Perrigo Company plc Impairment of Intangible Assets, Finite-lived
Perrigo Company plc (PRGO) reported Impairment of Intangible Assets, Finite-lived of $1.50 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsFinitelived · last filed 2026-02-26
- Perrigo Company plc impairment of intangible assets, finite-lived for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Perrigo Company plc impairment of intangible assets, finite-lived for the quarter ending 2025-06-28 was $1.50M.
- Perrigo Company plc impairment of intangible assets, finite-lived for the quarter ending 2024-12-31 was $38.60M.
- Perrigo Company plc impairment of intangible assets, finite-lived for the quarter ending 2016-04-02 was $273.40M.
- Perrigo Company plc impairment of intangible assets, finite-lived for fiscal 2025 was $1.50M, a 96.11% decline from fiscal 2024.
- Perrigo Company plc impairment of intangible assets, finite-lived for fiscal 2024 was $38.60M.
- Perrigo Company plc impairment of intangible assets, finite-lived for fiscal 2017 was $19.70M, a 97.04% decline from fiscal 2016.
- Perrigo Company plc impairment of intangible assets, finite-lived for fiscal 2016 was $665.60M.
| Period end | Impairment of Intangible Assets, Finite-lived 3 month | Impairment of Intangible Assets, Finite-lived 6 month | Impairment of Intangible Assets, Finite-lived 9 month | Impairment of Intangible Assets, Finite-lived 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.50M 10-K · filed 2026-02-26 | ||
| 2025-09-27 | $1.50M 10-Q · filed 2025-11-05 | |||
| 2025-06-28 | $1.50M 10-Q · filed 2025-08-06 | |||
| 2024-12-31 | $38.60M 10-Q · filed 2025-08-06 | $38.60M 10-K · filed 2026-02-26 | ||
| 2017-12-31 | $19.70M 10-K · filed 2018-03-01 | |||
| 2016-12-31 | $665.60M 10-K · filed 2018-03-01 | |||
| 2016-04-02 | $273.40M 10-Q · filed 2017-05-30 | |||
| 2015-12-31 | $185.10M 10-K · filed 2017-05-22 | |||
| 2015-06-27 | $0.00 10-K · filed 2017-05-22 | |||
| 2014-06-28 | -$6.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-05-22 | -$6.00M derived: sum of 2 quarters · filed 2017-05-22 | $0.00 10-K · filed 2017-05-22 | |
| 2014-03-29 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-05-07 | $6.00M 10-Q · filed 2014-05-07 | ||
| 2013-12-28 | $6.00M 10-Q · filed 2014-02-06 | |||
| 2013-06-29 | $0.00 derived: 10-KT 12 month − 10-Q 9 month · filed 2016-02-25 | $0.00 derived: sum of 2 quarters · filed 2016-02-25 | $0.00 10-KT · filed 2016-02-25 | |
| 2013-03-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-05-07 | $0.00 10-Q · filed 2014-05-07 | ||
| 2012-12-29 | $0.00 10-Q · filed 2014-02-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |